BeOne Medicines (BEIGF) Liabilities and Shareholders Equity (2015 - 2026)

BeOne Medicines (BEIGF) has reported Liabilities and Shareholders Equity for 12 consecutive years, with $9.2 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 45.68% year-over-year to $9.2 billion in Q2 2026; TTM through Jun 2026 was $33.6 billion, a 40.43% increase from a year earlier, with the FY2025 full-year figure at $8.2 billion, up 38.3% from the prior year.
• Liabilities and Shareholders Equity was $9.2 billion for Q2 2026 at BeOne Medicines, up from $8.6 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $9.2 billion in Q2 2026 and troughed at $5.5 billion in Q3 2023.
• A 5-year average of $6.7 billion and a median of $6.1 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity retreated 25.74% in 2023 and soared 46.43% in 2026, its largest moves.
• Over 5 years, Liabilities and Shareholders Equity stood at $6.4 billion in 2022, then decreased by 9.0% to $5.8 billion in 2023, then grew by 1.99% to $5.9 billion in 2024, then jumped by 38.3% to $8.2 billion in 2025, then rose by 12.05% to $9.2 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $9.2 billion (Q2 2026), $8.6 billion (Q1 2026), and $8.2 billion (Q4 2025), per Business Quant data.